CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma

Clinical Investigation of Chimeric Costimulatory Converting Receptor(CCCR)-Modified NK92 Cells in Previously Treated Advanced Non-small Cell Lung Carcinoma

The purpose of this clinical investigation is to evaluate the safety and effects of CCCR-modified NK92(CCCR-NK92)infusions in previously treated advanced non-small cell lung carcinoma(NSCLC).

Inclusion Criteria:

• 1.Male and female subjects with non-small cell lung carcinoma in patients with no available curative treatment options who have limited prognosis(≧3 months)with currently available therapies will be enrolled.
• 2.The last cytotoxic drug, radiotherapy or surgery≧4 weeks.
• 3.HB≧90g/L, ANC≧1.5×10e9/L, PLT≧80×10e9/L, TBIL≦1.5×upper limit of nomal, ALT/AST≦2.5×upper limit of nomal, ALT/AST≦5×upper limit of nomal if have liver metastasis, Cr≦1.5×upper limit of nomal or CCr≧60ml/min.

Exclusion Criteria:

• 1.Pregnancy or breastfeeding.
• 2.Known HIV, HBV or HCV infection.
• 3.Active antoimmune disease.
• 4.History of severe immediate hypersensitivity to any of the biological products including penicillin.
• 5.Severe psychiatric disorder which might interfere with the study treatment or examination.
• 6.Chronic heart failure NYHA≧III.
• 7.Simultaneous participation in another clinical trial within 4 weeks.